Core Viewpoint - The National Medical Products Administration (NMPA) has decided to revise the labeling of Montelukast formulations, including warnings about potential neuropsychiatric adverse reactions such as depression and suicidal tendencies, which has raised concerns among parents and the public [1][2]. Group 1: Regulatory Changes - The NMPA's announcement aims to alert doctors and patients to monitor for neuropsychiatric side effects while using Montelukast, but it does not imply that the drug is unsafe or should not be used [2][3]. - The revision of the drug's labeling is intended to ensure that healthcare providers weigh the risks and benefits of the medication during treatment [2]. Group 2: Usage Guidelines - Montelukast is commonly used for treating asthma and allergic rhinitis, and its benefits may vary depending on the condition being treated [2][3]. - Patients, especially children, should be closely monitored for any changes in behavior or mood during treatment, and any concerning symptoms should be reported to a healthcare provider [3][4]. Group 3: Precautions for Specific Populations - Parents should inform doctors of any previous neuropsychiatric history before their children use Montelukast, and they should monitor their children's emotional and behavioral changes closely [4]. - Pregnant and breastfeeding women are advised to avoid Montelukast unless absolutely necessary, as safety studies in these populations are lacking [4].

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations to enhance public medication safety, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's decision is based on the evaluation of adverse drug reactions, aiming to ensure safer medication use among the public [1] - The revised warning will include reports of neuropsychiatric adverse reactions across all age groups, including severe reactions such as depression and suicidal tendencies [1] Group 2: Patient Guidance - The new instructions recommend that if neuropsychiatric symptoms occur during treatment with Montelukast, the medication should be discontinued and medical attention sought [1] - Patients and caregivers are advised to be vigilant for neuropsychiatric adverse reactions and to inform healthcare providers if related symptoms arise during the medication period [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's announcement includes a warning that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [1] - It is advised that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1] - The revision also mandates the addition of stuttering as a reported adverse reaction based on post-marketing experience [1] Group 2: Expert Opinions - Ji Lianmei, founder of "Ask the Pharmacist," stated that Montelukast is not the first-line treatment for allergic rhinitis and asthma [1] - The incidence of psychiatric side effects, such as irritability and attention abnormalities, is reportedly higher in children [1] - It is emphasized that both adults and children should discontinue the medication and seek medical help if any neuropsychiatric symptoms arise, and a thorough assessment of benefits versus risks should be conducted before use [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's announcement includes a warning that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [1] - It is advised that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1] Group 2: Expert Opinions - Ji Lianmei, founder of "Ask the Pharmacist," stated that Montelukast sodium is not the first-choice medication for allergic rhinitis or asthma treatment [1] - The incidence of psychiatric side effects, such as irritability and attention abnormalities, is reportedly higher in children [1] - A thorough assessment of benefits versus risks is recommended before using the medication, and immediate discontinuation and medical consultation are advised if neuropsychiatric symptoms arise during treatment [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations to enhance public medication safety based on adverse drug reaction assessments [1][2] Group 1: Regulatory Changes - The NMPA requires all marketing authorization holders of Montelukast products to revise their instructions according to the new guidelines by March 12, 2026 [1] - The revisions must include updates to drug labels and any other content that aligns with the original approval [1] - Products manufactured after the filing date cannot use the original drug instructions [1] Group 2: Compliance and Enforcement - Marketing authorization holders must conduct in-depth research on the mechanisms of newly identified adverse reactions and implement effective measures for medication safety training [1] - Provincial drug supervision departments are tasked with ensuring compliance among marketing authorization holders regarding the instruction revisions and label updates [2] - The NMPA emphasizes that patients should carefully read drug instructions before use and adhere strictly to medical advice when using prescription medications [2]

Group 1 - Company has received the approval notice for the supplementary application of the drug "Xiaolin Baidu San" from the National Medical Products Administration [1] - "Xiaolin Baidu San" is a unique product of the company, primarily used for clearing heat and detoxifying, and treating symptoms related to urinary tract infections [1] - The company has invested approximately 28.15 million RMB in research and development for "Xiaolin Baidu San" and its pill form [1] Group 2 - The company has obtained a change in its drug production license from the Shandong Provincial Drug Administration, allowing for the addition of workshops, production lines, and production scope [4] - The production license now includes the addition of a comprehensive preparation workshop for pill production, enhancing the company's production capabilities [5] - The extension of the entrusted production validity period for various medications will help maintain stable production capacity and meet market demand [6]

Core Viewpoint - Company has received approval from the Shandong Provincial Drug Administration to expand its production capabilities, which is expected to positively impact its future operations [1] Summary by Sections Production License Update - The company has been granted permission to add a new workshop and production line for the production of tablets, specifically in the Heze City location [1] - The new workshop added is the Comprehensive Preparation VI workshop, which will focus on tablet production [1] Contract Manufacturing Extensions - The company has extended its contract manufacturing agreements for various products: - Loratadine tablets and Montelukast chewable tablets until July 16, 2028 - Ibuprofen sustained-release capsules and Ezetimibe tablets until July 16, 2028 - Pregabalin capsules until March 31, 2028 - Donepezil hydrochloride tablets until July 7, 2030 [1] Impact on Operations - The changes in the production license, including the addition of workshops and production lines, are expected to optimize the company's production structure [1] - This will help maintain stable production capacity and meet market demand, leading to a positive impact on the company's future operations [1]

Group 1 - The company is a leading player in the traditional Chinese medicine patch industry, with a stable growth in performance, achieving a revenue of 3.501 billion yuan in 2024 (+5.72%) and a net profit of 723 million yuan (+27.19%) [1] - In Q1 2025, the company reported a revenue of 1.021 billion yuan (+12.29%) and a net profit of 217 million yuan (+13.89%) [1] - The core products showed steady growth, with revenues from patches, tablets, capsules, ointments, and other categories reaching 2.115 billion, 356 million, 752 million, 128 million, and 148 million yuan respectively, with year-on-year growth rates of +3.35%, +35.60%, +5.66%, -7.09%, and -1.20% [1] Group 2 - The company has a strong market presence in external traditional Chinese medicine patches, with annual sales of the Tongluo Pain Relief Patch exceeding 1 billion yuan and the "Two Tigers" series products selling over 1 billion patches annually [1] - The company’s R&D expense ratio for 2024 was 3.76% (+0.45 percentage points), focusing on major diseases and products in orthopedics, respiratory, skin, and digestive systems [2] - The company signed a letter of intent for acquisition with Yingu Holdings Group in December 2024, aiming to acquire a controlling stake in Yingu Pharmaceutical, which aligns with its strategic planning and enhances its product matrix with high-tech nasal sprays and inhalants [2] Group 3 - The company expects net profits for 2025-2027 to be 831 million, 932 million, and 1.056 billion yuan, representing year-on-year growth of +15.0%, +12.2%, and +13.4% respectively [2] - The company maintains a leading brand advantage in the traditional Chinese medicine patch sector, with a solid market share for multiple products, and continues to enhance its product matrix through R&D and acquisitions [2]